Raptiva Off and Running

San Francisco - A study on Raptiva (efalizumab) shows patients with moderate-to-severe plaque psoriasis who received 12 weeks of treatment experienced a significant reduction in signs and symptoms, and patients who continued treatment to 24 weeks continued to benefit.

Related Videos
Related Content

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: Treating Atopic Dermatitis in the Winter

November 14th 2022

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: Treating Atopic Dermatitis in the Winter

November 14th 2022

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: Treating Atopic Dermatitis in the Winter

November 14th 2022

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023
Advertise
Contact Us
Job Board
Do Not Sell My Information
Terms and Conditions
Privacy Policy
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.